your market intelligence analyst
Search Results
168 results
Your search is now limited to «Inflammation» expert search.
FeedNavigator (EU) 10/13/2019 10:08
Antidiabetic agents refer to the diabetic and inflammatory hypotheses of AD and provide hope to find an effective drug for comprehensive therapy of the disease.
More from FeedNavigator (EU):
Fight Aging! 10/13/2019 09:54
A better understanding of the age-related changes in the immune system will allow us to craft therapies to limit detrimental aspects of inflammation, with the broader purpose of sharply reducing the number of people afflicted by AD.
More from Fight Aging!:
Business Wire 10/12/2019 04:45
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today complete results from a Phase 3, 12-week, pivotal study (JADE MONO-1) in patients aged 12 and older with moderate to severe atopic dermatitis (AD). Abrocitinib, an investigational oral Janus kinase 1 (JAK1) inhibitor, met all the co-primary and key secondary endpoints, which were related to skin clearance and itch relief compared to placebo. Safety data showed that both evaluated doses of abrocitinib (200mg and 100mg) were well.
More from Business Wire: 10/11/2019 12:00
One small papaya provides 95.6 mg of vitamin C. Vitamin C also has potential anti-inflammatory effects on the brain.
More from
Medical Xpress 10/08/2019 09:01
This treatment also reduced typical Alzheimer symptoms, including cerebral inflammation, blood vessel injury, and amyloid protein plaques.
More from Medical Xpress:
GlobeNewswire 10/08/2019 09:00
Approaching Alzheimer’s disease as an immunological disease: role of biomarkers” Dr. Barnum will discuss how innate immune regulation causes chronic inflammation and development of Alzheimer’s disease, and how approaching AD as an immunological disease changes the clinical strategy, especially when developing biomarkers.
More from GlobeNewswire:
PR Newswire 10/08/2019 06:45
INDIANAPOLIS, Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 28th annual European Academy of Dermatology and Venereology (EADV) Congress taking place Oct....
More from PR Newswire:
BIOENGINEER.ORG 10/07/2019 00:36
As chronic neuroinflammation is a common feature seen early in both VCID and Alzheimer’s disease progression, Van Eldik’s work will test the idea that excessive inflammation in the brain driven by p38-MAPK worsens dementia symptoms and is therefore a good target for therapeutic intervention.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications